Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ANAB 01.07.2025
Drug:rosnilimab-unknown rosnilimab
Drug:rosnilimab-unknown rosnilimab
Drug:ANB033-unknown ANB033
Drug:ANB101-unknown ANB101
Diseases:rheumatoid arthritis
Diseases:ulcerative colitis
Date of Upcoming Event:2025-01-14
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
About Gravity Analytica
Recent News
- 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
- 01.07.2025 - Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- 12.11.2024 - Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
Recent Filings
A live webcast of the presentation will be available on the investor section of the Anaptys website athttp://ir.anaptysbio.com/events. A replay of the webcast will be available for at least 30 days following the event.About AnaptysAnaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, soon to enter clinical development. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli(dostarlimab-gxly)) and an anti-TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visitwww.AnaptysBio.comor follow us onLinkedIn.Contact:
Source: AnaptysBio, Inc.